FDA Panel Backs Galleri Blood Test for More Than 50 Cancers, and What the Vote Means for Patients

A blood test that can look for signs of dozens of cancers at once has moved an important step closer to formal FDA approval, but the closely divided vote over whether the test is effective shows why patients should view the technology with both optimism and care.

On September 23, 2026, the Food and Drug Administration’s Molecular and Clinical Genetics Panel backed GRAIL’s Galleri multi-cancer blood test on all three questions. The panel voted 10-0 that there is reasonable assurance the test is safe, 6-4 that there is reasonable assurance it is effective, and 7-2, with one abstention, that Galleri’s benefits outweigh its risks for adults covered by the proposed indication.

For patients, the appeal is easy to understand. Most cancer screening today looks for one disease at a time, and many cancers still have no recommended screening test for people without symptoms. Galleri uses a single blood draw to search for cancer-related DNA patterns and, when it detects a signal, attempts to identify where in the body that signal originated. GRAIL is seeking FDA approval to use the prescription test in adults 50 and older.

The panel’s recommendation does not mean Galleri is now FDA-approved. Advisory committees provide independent expert advice, but the FDA makes the final decision on a premarket approval application and is not legally required to follow the panel’s recommendation. A final decision is expected in the coming months.

Galleri is already available by prescription as a laboratory-developed test, but it has not received FDA approval. Formal approval would put the test through a federal medical-device review that could carry broader significance for physicians, patients, insurers and a growing field of companies developing multi-cancer blood tests.

The panel’s unanimous safety vote was straightforward. The harder question was effectiveness.

Six members voted that there was reasonable assurance Galleri is effective, while four voted against that conclusion. That narrower vote reflects the unusual challenge presented by a screening test that can find some cancers doctors currently have few ways to detect while also missing many cancers that are present.

In the U.S. PATHFINDER 2 study, Galleri detected 35% of cancers diagnosed in participants during the following 12 months. Its specificity was 99.85%, meaning false-positive results were uncommon. In the NHS-Galleri analysis, sensitivity was 31.6%, and specificity was 99.74%.

Those percentages deserve a little plain-English translation. Galleri was very good at avoiding a cancer signal in people who did not have cancer. But among people who were diagnosed with cancer during the study period, the test detected only about one-third of those cancers.

A negative Galleri result therefore cannot be treated as proof that someone is cancer-free. The FDA’s proposed language specifically warns that a “No Cancer Signal Detected” result does not rule out cancer and that patients should continue guideline-recommended screening. Galleri is intended to supplement mammograms, colon cancer screening, cervical screening and other established approaches rather than replace them.

That distinction could become one of the most important messages physicians have to convey if Galleri receives FDA approval. A reassuring blood test can feel powerful to a patient, particularly someone worried about cancer. But reassurance becomes risky if it leads someone to skip a mammogram, colonoscopy, or evaluation of a new symptom because a Galleri result was negative.

A positive result brings a different kind of uncertainty. Galleri does not diagnose cancer. A detected signal, along with the test’s prediction of where that signal originated, must be followed by an appropriate diagnostic workup. Depending on the suspected cancer, that could include imaging, specialist evaluation, endoscopy, or biopsy.

The test performed well at limiting false alarms. FDA data showed false-positive rates of 0.15% in PATHFINDER 2 and 0.26% in the NHS-Galleri analysis. Among positive results, cancer was ultimately confirmed in 77% of cases in PATHFINDER 2 and 66.2% in the NHS-Galleri analysis used in the FDA review.

Even a relatively low false-positive rate has consequences when a screening test is used across a large population. A person who hears that a blood test has found a possible cancer signal can face days or weeks of anxiety along with additional scans, procedures, and medical appointments before learning whether cancer is actually present.

At the same time, Galleri offers something that conventional screening often cannot: the possibility of detecting cancers for which there is currently no routine population screening program.

That potential is part of what makes the technology so compelling. Pancreatic, ovarian, and several other cancers are often discovered after symptoms develop, when disease can be more advanced. A blood test capable of identifying even a portion of those cancers sooner could give doctors another way to find disease before a patient would otherwise come to medical attention.

The unresolved question is how often Galleri truly accomplishes that goal early enough to improve outcomes.

The words “early detection” became an important part of the FDA panel’s discussion. GRAIL’s proposed indication describes Galleri as a test for the “early detection” of multiple cancers, but FDA reviewers specifically asked the panel to consider whether the test’s performance by cancer stage supports that description. The agency also asked whether an alternative indication simply describing the “detection” of multiple cancers would be more appropriate if the evidence does not support the word “early.”

That is more than a labeling technicality. To a patient, “early detection” can reasonably suggest that a test is particularly good at finding cancer in its earliest stages.

Galleri’s performance becomes stronger as some cancers become more advanced, and the broader clinical evidence is mixed. The large randomized NHS-Galleri trial enrolled more than 142,000 adults and tested whether adding Galleri to usual care would reduce diagnoses of stage III and IV cancers among 12 prespecified cancer types. It did not meet that primary endpoint. The incidence of stage III or IV cancer was not significantly lower in the Galleri group after three screening rounds.

The same trial produced findings that offer a more encouraging side of the story. Stage IV cancers were less common in the Galleri group, and more stage I and II cancers were diagnosed among participants offered the test. Researchers have said additional follow-up is needed to determine how those patterns develop over time.

For cancer patients, the difference between finding disease at an earlier stage and finding it after it has spread can be enormous. Treatment options, the possibility of surgery and the likelihood of treatment with curative intent can all change as cancer advances. That is why the promise of multi-cancer detection deserves serious attention — and why evidence that a test actually shifts cancer toward earlier diagnosis deserves equally careful scrutiny.

The FDA could approve Galleri with the indication proposed by GRAIL, modify the language, impose warnings or limitations, or require additional evidence. The agency also asked its advisers to discuss whether post-approval studies would be useful if it clears the test based on the existing data.

The September 23 vote is significant because Galleri is farther along in the FDA process than other multi-cancer screening tests. No FDA-approved test currently offers comparable screening for numerous cancer types through a single blood draw. A Galleri approval could therefore help establish how regulators evaluate an entirely new category of cancer screening technology.

For patients, however, the most important takeaway is much simpler.

The panel’s vote is encouraging for Galleri, but it does not transform one blood draw into a definitive cancer screen. A positive result still needs a diagnostic workup, a negative result cannot rule out cancer, and established screening remains important.

What Galleri could offer is another potentially valuable piece of information in the effort to find cancers that medicine has historically struggled to detect before symptoms appear.

The FDA’s final decision will determine how that promise is described to patients and physicians. Just as important will be what happens after approval, when a test developed in clinical studies begins influencing real conversations between doctors and millions of people wondering what a few tubes of blood can truly tell them about cancer.